High-dose chemotherapy and stem-cell rescue in the treatment of high- risk breast cancer: Prognostic indicators of progression-free and overall survival

George Somlo, James H. Doroshow, Stephen J. Forman, Tamara Odom-Maryon, Jennifer Lee, Warren Chow, Victor Hamasaki, Lucille Leong, Robert Morgan, Kim Margolin, James Raschko, Stephen Shibata, Merry Tetef, Yun Yen, Jean Simpson, Arturo Molina

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Purpose: To examine the predictive value of tumor-and treatment-specific prognostic indicators of relapse-free survival (RFS) and overall survival (OS) in patients with high-risk breast cancer (HRBC) treated with highdose chemotherapy (HDCT)and stem-eel (rescue. Patients and Methods: Between June 1989 and September 1994, 114 patients with HRBC (stage II with ≤ 10 axillary lymph nodes involved, stage IIIA, and stage IIIB inflammatory carcinoma) received adjuvant chemotherapy followed by HDCT with etoposide, cyclaphosphamide, and either doxorubicin (CAVP) or cisplatin (CCVP). Variables analyzed included stage, tumor size, number of axillary nodes involved, grade and receptor status, and types of adjuvant chemotherapy and radiation therapy and HDCT. Results: With a median follow-up time of 46 months (range, 23 to 93), Kaplan-Meier estimates of 3.5-year OS for stage II, IIIA, and IlIB HRBC are 82% (95% confidence interval [CI], 67% to 97%), 79% (95% CI, 67% to 91%), and 72% 495% CI, 53% to 91%); RFS estimates are 71% 495% CI, 56% to 85%), 57% 495% CI, 43% to 72%), and 50% (95% CI, 29% to 71%) irrespective of the HDCT regimen. In univariate analysis, the risk of relapse was lower for patients with progesterone receptor (PR)-positive tumors (risk ratio [RR], 0.43; 95% CI, 0.22 to 0.81; P = .01) and higher for patients with inflammatory carcinoma (RR, 2.20; 95% CI, 1.02 to 4.76; P = .05). OS was better for patients with PR (RR, 0.16; 95% CI, 0.05 to 0.55; P = .003) and estrogen receptor (ER)-positive tumors (RR, 0.42; 95% CI, 0.17 to 1.02; P = .05); OS was worse for patients with high-grade primary tumors (RR, 4.08; 95% CI, 1.21-13.7; P = .02). In multivariate analysis, PR positivity was associated with improved RFS (P = .01) and os (P = .001). Conclusion: HDCT in selected patients with HRBC is safe and warrants further evaluation. Patients with receptor-negative, high-grade, or inflammatory tumors require improvement in their therapeutic options. Better assessment of the role of HDCT awaits completion of ongoing randomized trials.

Original languageEnglish
Pages (from-to)2882-2893
Number of pages12
JournalJournal of Clinical Oncology
Volume15
Issue number8
DOIs
Publication statusPublished - Jan 1 1997
Externally publishedYes

Fingerprint

Disease-Free Survival
Stem Cells
Confidence Intervals
Breast Neoplasms
Drug Therapy
Survival
Odds Ratio
Progesterone Receptors
Therapeutics
Recurrence
Neoplasms
Adjuvant Chemotherapy
Carcinoma
Eels
Kaplan-Meier Estimate
Etoposide
Estrogen Receptors
Doxorubicin
Cisplatin
Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

High-dose chemotherapy and stem-cell rescue in the treatment of high- risk breast cancer : Prognostic indicators of progression-free and overall survival. / Somlo, George; Doroshow, James H.; Forman, Stephen J.; Odom-Maryon, Tamara; Lee, Jennifer; Chow, Warren; Hamasaki, Victor; Leong, Lucille; Morgan, Robert; Margolin, Kim; Raschko, James; Shibata, Stephen; Tetef, Merry; Yen, Yun; Simpson, Jean; Molina, Arturo.

In: Journal of Clinical Oncology, Vol. 15, No. 8, 01.01.1997, p. 2882-2893.

Research output: Contribution to journalArticle

Somlo, G, Doroshow, JH, Forman, SJ, Odom-Maryon, T, Lee, J, Chow, W, Hamasaki, V, Leong, L, Morgan, R, Margolin, K, Raschko, J, Shibata, S, Tetef, M, Yen, Y, Simpson, J & Molina, A 1997, 'High-dose chemotherapy and stem-cell rescue in the treatment of high- risk breast cancer: Prognostic indicators of progression-free and overall survival', Journal of Clinical Oncology, vol. 15, no. 8, pp. 2882-2893. https://doi.org/10.1200/JCO.1997.15.8.2882
Somlo, George ; Doroshow, James H. ; Forman, Stephen J. ; Odom-Maryon, Tamara ; Lee, Jennifer ; Chow, Warren ; Hamasaki, Victor ; Leong, Lucille ; Morgan, Robert ; Margolin, Kim ; Raschko, James ; Shibata, Stephen ; Tetef, Merry ; Yen, Yun ; Simpson, Jean ; Molina, Arturo. / High-dose chemotherapy and stem-cell rescue in the treatment of high- risk breast cancer : Prognostic indicators of progression-free and overall survival. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 8. pp. 2882-2893.
@article{367354ed022b40cbadc69597c976648e,
title = "High-dose chemotherapy and stem-cell rescue in the treatment of high- risk breast cancer: Prognostic indicators of progression-free and overall survival",
abstract = "Purpose: To examine the predictive value of tumor-and treatment-specific prognostic indicators of relapse-free survival (RFS) and overall survival (OS) in patients with high-risk breast cancer (HRBC) treated with highdose chemotherapy (HDCT)and stem-eel (rescue. Patients and Methods: Between June 1989 and September 1994, 114 patients with HRBC (stage II with ≤ 10 axillary lymph nodes involved, stage IIIA, and stage IIIB inflammatory carcinoma) received adjuvant chemotherapy followed by HDCT with etoposide, cyclaphosphamide, and either doxorubicin (CAVP) or cisplatin (CCVP). Variables analyzed included stage, tumor size, number of axillary nodes involved, grade and receptor status, and types of adjuvant chemotherapy and radiation therapy and HDCT. Results: With a median follow-up time of 46 months (range, 23 to 93), Kaplan-Meier estimates of 3.5-year OS for stage II, IIIA, and IlIB HRBC are 82{\%} (95{\%} confidence interval [CI], 67{\%} to 97{\%}), 79{\%} (95{\%} CI, 67{\%} to 91{\%}), and 72{\%} 495{\%} CI, 53{\%} to 91{\%}); RFS estimates are 71{\%} 495{\%} CI, 56{\%} to 85{\%}), 57{\%} 495{\%} CI, 43{\%} to 72{\%}), and 50{\%} (95{\%} CI, 29{\%} to 71{\%}) irrespective of the HDCT regimen. In univariate analysis, the risk of relapse was lower for patients with progesterone receptor (PR)-positive tumors (risk ratio [RR], 0.43; 95{\%} CI, 0.22 to 0.81; P = .01) and higher for patients with inflammatory carcinoma (RR, 2.20; 95{\%} CI, 1.02 to 4.76; P = .05). OS was better for patients with PR (RR, 0.16; 95{\%} CI, 0.05 to 0.55; P = .003) and estrogen receptor (ER)-positive tumors (RR, 0.42; 95{\%} CI, 0.17 to 1.02; P = .05); OS was worse for patients with high-grade primary tumors (RR, 4.08; 95{\%} CI, 1.21-13.7; P = .02). In multivariate analysis, PR positivity was associated with improved RFS (P = .01) and os (P = .001). Conclusion: HDCT in selected patients with HRBC is safe and warrants further evaluation. Patients with receptor-negative, high-grade, or inflammatory tumors require improvement in their therapeutic options. Better assessment of the role of HDCT awaits completion of ongoing randomized trials.",
author = "George Somlo and Doroshow, {James H.} and Forman, {Stephen J.} and Tamara Odom-Maryon and Jennifer Lee and Warren Chow and Victor Hamasaki and Lucille Leong and Robert Morgan and Kim Margolin and James Raschko and Stephen Shibata and Merry Tetef and Yun Yen and Jean Simpson and Arturo Molina",
year = "1997",
month = "1",
day = "1",
doi = "10.1200/JCO.1997.15.8.2882",
language = "English",
volume = "15",
pages = "2882--2893",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - High-dose chemotherapy and stem-cell rescue in the treatment of high- risk breast cancer

T2 - Prognostic indicators of progression-free and overall survival

AU - Somlo, George

AU - Doroshow, James H.

AU - Forman, Stephen J.

AU - Odom-Maryon, Tamara

AU - Lee, Jennifer

AU - Chow, Warren

AU - Hamasaki, Victor

AU - Leong, Lucille

AU - Morgan, Robert

AU - Margolin, Kim

AU - Raschko, James

AU - Shibata, Stephen

AU - Tetef, Merry

AU - Yen, Yun

AU - Simpson, Jean

AU - Molina, Arturo

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Purpose: To examine the predictive value of tumor-and treatment-specific prognostic indicators of relapse-free survival (RFS) and overall survival (OS) in patients with high-risk breast cancer (HRBC) treated with highdose chemotherapy (HDCT)and stem-eel (rescue. Patients and Methods: Between June 1989 and September 1994, 114 patients with HRBC (stage II with ≤ 10 axillary lymph nodes involved, stage IIIA, and stage IIIB inflammatory carcinoma) received adjuvant chemotherapy followed by HDCT with etoposide, cyclaphosphamide, and either doxorubicin (CAVP) or cisplatin (CCVP). Variables analyzed included stage, tumor size, number of axillary nodes involved, grade and receptor status, and types of adjuvant chemotherapy and radiation therapy and HDCT. Results: With a median follow-up time of 46 months (range, 23 to 93), Kaplan-Meier estimates of 3.5-year OS for stage II, IIIA, and IlIB HRBC are 82% (95% confidence interval [CI], 67% to 97%), 79% (95% CI, 67% to 91%), and 72% 495% CI, 53% to 91%); RFS estimates are 71% 495% CI, 56% to 85%), 57% 495% CI, 43% to 72%), and 50% (95% CI, 29% to 71%) irrespective of the HDCT regimen. In univariate analysis, the risk of relapse was lower for patients with progesterone receptor (PR)-positive tumors (risk ratio [RR], 0.43; 95% CI, 0.22 to 0.81; P = .01) and higher for patients with inflammatory carcinoma (RR, 2.20; 95% CI, 1.02 to 4.76; P = .05). OS was better for patients with PR (RR, 0.16; 95% CI, 0.05 to 0.55; P = .003) and estrogen receptor (ER)-positive tumors (RR, 0.42; 95% CI, 0.17 to 1.02; P = .05); OS was worse for patients with high-grade primary tumors (RR, 4.08; 95% CI, 1.21-13.7; P = .02). In multivariate analysis, PR positivity was associated with improved RFS (P = .01) and os (P = .001). Conclusion: HDCT in selected patients with HRBC is safe and warrants further evaluation. Patients with receptor-negative, high-grade, or inflammatory tumors require improvement in their therapeutic options. Better assessment of the role of HDCT awaits completion of ongoing randomized trials.

AB - Purpose: To examine the predictive value of tumor-and treatment-specific prognostic indicators of relapse-free survival (RFS) and overall survival (OS) in patients with high-risk breast cancer (HRBC) treated with highdose chemotherapy (HDCT)and stem-eel (rescue. Patients and Methods: Between June 1989 and September 1994, 114 patients with HRBC (stage II with ≤ 10 axillary lymph nodes involved, stage IIIA, and stage IIIB inflammatory carcinoma) received adjuvant chemotherapy followed by HDCT with etoposide, cyclaphosphamide, and either doxorubicin (CAVP) or cisplatin (CCVP). Variables analyzed included stage, tumor size, number of axillary nodes involved, grade and receptor status, and types of adjuvant chemotherapy and radiation therapy and HDCT. Results: With a median follow-up time of 46 months (range, 23 to 93), Kaplan-Meier estimates of 3.5-year OS for stage II, IIIA, and IlIB HRBC are 82% (95% confidence interval [CI], 67% to 97%), 79% (95% CI, 67% to 91%), and 72% 495% CI, 53% to 91%); RFS estimates are 71% 495% CI, 56% to 85%), 57% 495% CI, 43% to 72%), and 50% (95% CI, 29% to 71%) irrespective of the HDCT regimen. In univariate analysis, the risk of relapse was lower for patients with progesterone receptor (PR)-positive tumors (risk ratio [RR], 0.43; 95% CI, 0.22 to 0.81; P = .01) and higher for patients with inflammatory carcinoma (RR, 2.20; 95% CI, 1.02 to 4.76; P = .05). OS was better for patients with PR (RR, 0.16; 95% CI, 0.05 to 0.55; P = .003) and estrogen receptor (ER)-positive tumors (RR, 0.42; 95% CI, 0.17 to 1.02; P = .05); OS was worse for patients with high-grade primary tumors (RR, 4.08; 95% CI, 1.21-13.7; P = .02). In multivariate analysis, PR positivity was associated with improved RFS (P = .01) and os (P = .001). Conclusion: HDCT in selected patients with HRBC is safe and warrants further evaluation. Patients with receptor-negative, high-grade, or inflammatory tumors require improvement in their therapeutic options. Better assessment of the role of HDCT awaits completion of ongoing randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=0030838930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030838930&partnerID=8YFLogxK

U2 - 10.1200/JCO.1997.15.8.2882

DO - 10.1200/JCO.1997.15.8.2882

M3 - Article

C2 - 9256132

AN - SCOPUS:0030838930

VL - 15

SP - 2882

EP - 2893

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -